Potential of the quadrivalent human papillomavirus vaccine in the prevention and treatment of cervical cancer

Suzanne M. Garland, Darron Brown

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Introduction: Genital human papillomaviruses (HPVs) are readily transmissible and commonly acquired after sexual debut. With HPV being uncultivatable, it has taken the application of molecular biology to describe the virus' natural history, although it has also given us sensitive diagnostic tools, as well as underpinning the development of prophylactic viral-like particle (VLP) vaccines. Molecular epidemiology proved oncogenic HPVs as causing 100% of cervical, plus a proportion of, anogenital and oropharyngeal cancers. The quadrivalent vaccine containing VLPs 6, 11 (cause > 90% of genital warts), 16, 18, (causing 70% of cervical cancers) has shown in Phase III trials excellent safety, high efficacy and immunogenicity. Areas covered: This review looks at Phase III clinical trial data, plus vaccine effectiveness reported in real-world situations. Expert opinion: Given the remarkable early successes of vaccine effectiveness in reduction of HPV-vaccine-related infections in vaccine-eligible age females, rapid reduction in genital warts (first marker of disease reduction and herd immunity) and high-grade cervical lesions, in countries where vaccine has high coverage of target populations, vaccination should ultimately translate into reductions in HPV-related neoplasias. The greatest success from this vaccine will only be realized when it is rolled out effectively, with high coverage to those parts in the world with the highest burden of disease. We have the tools; we now need to use them.

Original languageEnglish
Pages (from-to)527-534
Number of pages8
JournalExpert Opinion on Biological Therapy
Volume14
Issue number4
DOIs
StatePublished - 2014

Fingerprint

Papillomavirus Vaccines
Uterine Cervical Neoplasms
Vaccines
Condylomata Acuminata
Therapeutics
Herd Immunity
Oropharyngeal Neoplasms
Phase III Clinical Trials
Molecular biology
Molecular Epidemiology
Health Services Needs and Demand
Expert Testimony
Natural History
Viruses
Virion
Molecular Biology
Vaccination
Safety
Infection

Keywords

  • Cervical cancer
  • Genital warts
  • Human papillomavirus
  • Prophylactic vaccine

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery

Cite this

Potential of the quadrivalent human papillomavirus vaccine in the prevention and treatment of cervical cancer. / Garland, Suzanne M.; Brown, Darron.

In: Expert Opinion on Biological Therapy, Vol. 14, No. 4, 2014, p. 527-534.

Research output: Contribution to journalArticle

@article{2663b8c1e63c4e83abd74582ef4977aa,
title = "Potential of the quadrivalent human papillomavirus vaccine in the prevention and treatment of cervical cancer",
abstract = "Introduction: Genital human papillomaviruses (HPVs) are readily transmissible and commonly acquired after sexual debut. With HPV being uncultivatable, it has taken the application of molecular biology to describe the virus' natural history, although it has also given us sensitive diagnostic tools, as well as underpinning the development of prophylactic viral-like particle (VLP) vaccines. Molecular epidemiology proved oncogenic HPVs as causing 100{\%} of cervical, plus a proportion of, anogenital and oropharyngeal cancers. The quadrivalent vaccine containing VLPs 6, 11 (cause > 90{\%} of genital warts), 16, 18, (causing 70{\%} of cervical cancers) has shown in Phase III trials excellent safety, high efficacy and immunogenicity. Areas covered: This review looks at Phase III clinical trial data, plus vaccine effectiveness reported in real-world situations. Expert opinion: Given the remarkable early successes of vaccine effectiveness in reduction of HPV-vaccine-related infections in vaccine-eligible age females, rapid reduction in genital warts (first marker of disease reduction and herd immunity) and high-grade cervical lesions, in countries where vaccine has high coverage of target populations, vaccination should ultimately translate into reductions in HPV-related neoplasias. The greatest success from this vaccine will only be realized when it is rolled out effectively, with high coverage to those parts in the world with the highest burden of disease. We have the tools; we now need to use them.",
keywords = "Cervical cancer, Genital warts, Human papillomavirus, Prophylactic vaccine",
author = "Garland, {Suzanne M.} and Darron Brown",
year = "2014",
doi = "10.1517/14712598.2014.880418",
language = "English",
volume = "14",
pages = "527--534",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Potential of the quadrivalent human papillomavirus vaccine in the prevention and treatment of cervical cancer

AU - Garland, Suzanne M.

AU - Brown, Darron

PY - 2014

Y1 - 2014

N2 - Introduction: Genital human papillomaviruses (HPVs) are readily transmissible and commonly acquired after sexual debut. With HPV being uncultivatable, it has taken the application of molecular biology to describe the virus' natural history, although it has also given us sensitive diagnostic tools, as well as underpinning the development of prophylactic viral-like particle (VLP) vaccines. Molecular epidemiology proved oncogenic HPVs as causing 100% of cervical, plus a proportion of, anogenital and oropharyngeal cancers. The quadrivalent vaccine containing VLPs 6, 11 (cause > 90% of genital warts), 16, 18, (causing 70% of cervical cancers) has shown in Phase III trials excellent safety, high efficacy and immunogenicity. Areas covered: This review looks at Phase III clinical trial data, plus vaccine effectiveness reported in real-world situations. Expert opinion: Given the remarkable early successes of vaccine effectiveness in reduction of HPV-vaccine-related infections in vaccine-eligible age females, rapid reduction in genital warts (first marker of disease reduction and herd immunity) and high-grade cervical lesions, in countries where vaccine has high coverage of target populations, vaccination should ultimately translate into reductions in HPV-related neoplasias. The greatest success from this vaccine will only be realized when it is rolled out effectively, with high coverage to those parts in the world with the highest burden of disease. We have the tools; we now need to use them.

AB - Introduction: Genital human papillomaviruses (HPVs) are readily transmissible and commonly acquired after sexual debut. With HPV being uncultivatable, it has taken the application of molecular biology to describe the virus' natural history, although it has also given us sensitive diagnostic tools, as well as underpinning the development of prophylactic viral-like particle (VLP) vaccines. Molecular epidemiology proved oncogenic HPVs as causing 100% of cervical, plus a proportion of, anogenital and oropharyngeal cancers. The quadrivalent vaccine containing VLPs 6, 11 (cause > 90% of genital warts), 16, 18, (causing 70% of cervical cancers) has shown in Phase III trials excellent safety, high efficacy and immunogenicity. Areas covered: This review looks at Phase III clinical trial data, plus vaccine effectiveness reported in real-world situations. Expert opinion: Given the remarkable early successes of vaccine effectiveness in reduction of HPV-vaccine-related infections in vaccine-eligible age females, rapid reduction in genital warts (first marker of disease reduction and herd immunity) and high-grade cervical lesions, in countries where vaccine has high coverage of target populations, vaccination should ultimately translate into reductions in HPV-related neoplasias. The greatest success from this vaccine will only be realized when it is rolled out effectively, with high coverage to those parts in the world with the highest burden of disease. We have the tools; we now need to use them.

KW - Cervical cancer

KW - Genital warts

KW - Human papillomavirus

KW - Prophylactic vaccine

UR - http://www.scopus.com/inward/record.url?scp=84896112874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896112874&partnerID=8YFLogxK

U2 - 10.1517/14712598.2014.880418

DO - 10.1517/14712598.2014.880418

M3 - Article

VL - 14

SP - 527

EP - 534

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 4

ER -